Shopping Cart
- Remove All
- Your shopping cart is currently empty
Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $179 | In Stock | |
5 mg | $579 | In Stock | |
10 mg | $826 | In Stock | |
25 mg | $1,220 | In Stock | |
50 mg | $1,650 | In Stock |
Description | Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease. |
Targets&IC50 | IL-1β:40.8 pM (marmoset), IL-1β:43.6 pM (human) |
In vitro | Dose-dependently, Canakinumab (0-7 nM) represses IL-6 production in marmoset peripheral blood mononuclear cells, demonstrating IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively[2]. Effectively, Canakinumab competes with IL-1RI and IL-1RII for binding to IL-1b[2]. |
Alias | Ilaris, ACZ 885 |
Molecular Weight | 145.18 kDa |
Cas No. | 914613-48-2 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.